Biosafety assays for the diagnosis and prediction of drug-related complement pathology

Información del proyecto

Biosafety

Identificador del acuerdo de subvención: 952520

DOI

10.3030/952520

Proyecto cerrado

Fecha de la firma de la CE 6 Julio 2020

Fecha de inicio 1 Septiembre 2020

Fecha de finalización 31 Agosto 2023

Financiado con arreglo a

• Twinning of research institutions

Coste total

€ 900 000,00

Aportación de la UE

€ 900 000,00

Coordinado por

SEMMELWEIS EGYETEM
Hungary

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Resultado final

Documents, reports (8)

“BIOSAFETY” Joint Summer School (A and B)

A joint summer school will be organised in Budapest

Report about the meetings with interest groups from industry

Meetings with interest groups from industry will be reported

KPIs definition for “BIOSAFETY”

This list of putative KPIs will be thoroughly discussed with the expert partnering institutions and a final list will be compiled

Impact assessment by the end of the project and forecast of the following 3-year period

Impact assessment will be performed in a 3year window by the end of the project

"„The industrial day"" and ""Knowledge Transfer Zone"" through meetings between research institutions and enterprises"

Experts from the partnering institutions will be invited to provide inspirational lectures and topic related events to stimulate brainstormingExperts from the partnering institutions will be invited to provide inspirational lectures and topic related events to stimulate brainstorming

Impact assessment in the 3-year period prior to “BIOSAFETY” for all KPIs

Impact assessment will be performed in a 3year window at the begining of the project

Publication history of Semmelw in the last 3 years
“BIOSAFETY” Thematic Workshop (A and B)

Thematic workshop for example biosafety markers un indispensable tool to predict unwanted side effects relevant to BIOSAFETY project will be organised

Open Research Data Pilot (2)

First data Management Plan
Final Data Management Plan

Websites, patent fillings, videos etc. (1)

Development of the project logo/brand and brochure/flyer

Developing a project logo and setting up a project website are two critical steps which will pave the way for an effective Public Relations PR strategy for BIOSAFETYA brochure and flyer will also be developed in the first year of the project to support the dissemination of BIOSAFETY in different events They will be revised when needed

Publicaciones

Peer reviewed articles (15)

Effect of the Addition of Alginate and/or Tetracycline on Brushite Cement Properties

Autores: Claudia Morilla, Elianis Perdomo, Ana Karla Hernández, Ramcy Regalado, Amisel Almirall, Gastón Fuentes, Yaima Campos Mora, Timo Schomann, Alan Chan, Luis J. Cruz
Publicado en: Molecules, Edición 26/11, 2021, Página(s) 3272, ISSN 1420-3049
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/molecules26113272

Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy

Autores: Yang Hao,Chih Kit Chung,Zhenfeng Yu,Ruben V. Huis in ‘t Veld,Ferry A. Ossendorp,Peter ten Dijke,and Luis J. Cruz.
Publicado en: Pharmaceutics, 2022, ISSN 1999-4923
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14010120

A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor

Autores: Dezsi L, Meszaros T, Kozma GT, H-Velkei M, Olah CZ, Szabo M, Patko Zs, Fulop T, Hennies M, Szebeni M, Barta BA, Merkely B, Radovits T, and Szebeni J
Publicado en: GeroScience, Edición 44(2), 2022, Página(s) 597–618, ISSN 2509-2723
Editor: Springer
DOI: 10.1007/s11357-021-00495-y

Zinc-Phthalocyanine-Loaded Extracellular Vesicles Increase Efficacy and Selectivity of Photodynamic Therapy in Co-Culture and Preclinical Models of Colon Cancer

Autores: Pablo Lara, Ruben V. Huis in ‘t Veld, Carla Jorquera-Cordero, Alan B. Chan, Ferry Ossendorp, Luis J. Cruz
Publicado en: Pharmaceutics, Edición 13/10, 2021, Página(s) 1547, ISSN 1999-4923
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics13101547

The Incorporation of Etanercept into a Porous Tri-Layer Scaffold for Restoring and Repairing Cartilage Tissue

Autores: Campos, Yaima; Fuentes, Gastón; Almirall, Amisel; Que, Ivo; Schomann, Timo; Chung, Chih Kit; Jorquera Cordero, Carla; Quintanilla Sierra, Luis; Rodríguez Cabello, José Carlos; Chan, Alan; Cruz, Luis
Publicado en: Pharmaceutics, Edición 1, 2022, ISSN 1999-4923
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14020282

Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines

Autores: Szebeni J, Storm G, Ljubimova JY, Castells M, Phillips EJ, Turjeman K, Barenholz Y, Crommelin DJA and Dobrovolskaia MA
Publicado en: Nature Nanotechnology, Edición 17(4), 2022, Página(s) 337-346, ISSN 1748-3387
Editor: Nature Publishing Group
DOI: 10.1038/s41565-022-01071-x

Eculizumab suppresses zymosan-induced release of inflammatory cytokinesIL-1α, IL-1β, IFN-γ and IL-2 in autologous serum-substituted PBMC cultures:Relevance to cytokine storm in Covid-19

Autores: Bakos T. Kozma GT, Szebeni J, Szénási G.
Publicado en: Biomedicine & Pharmacotherapy, Edición 166, 2023, Página(s) 115294, ISSN 0753-3322
Editor: Elsevier Masson
DOI: 10.1016/j.biopha.2023.115294

Zymosan Particle-Induced Hemodynamic, Cytokine and Blood Cell Changes in Pigs: An Innate Immune Stimulation Model with Relevance to Cytokine Storm Syndrome and Severe COVID-19

Autores: Kokeny G, Bakos T, Barta BA, Nagy GV, Meszaros T, Kozma GT, Szabo A, Szebeni J, Merkely B, Radovits T
Publicado en: International Journal of Molecular Sciences, Edición 24, 2023, Página(s) 18, ISSN 1661-6596
Editor: MDPI
DOI: 10.3390/ijms24021138

Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: Benefits of slow infusion

Autores: Gergely Milosevits,Tamás Mészáros, Erik Őrfi PharmD, Tamás Bakos, Miklós Garami, Gábor Kovács, László Dézsi, Péter Hamar, Balázs Győrffy, András Szabó, Gábor Szénási,János Szebeni.
Publicado en: Nanomedicine: Nanotechnology, Biology and Medicine, 2021, ISSN 1549-9634
Editor: Elsevier BV
DOI: 10.1016/j.nano.2021.102366

Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm

Autores: Gergely Tibor Kozma, Tamás Mészáros, Tamás Bakos, Mark Hennies, Dániel Bencze, Barbara Uzonyi, Balázs Győrffy, Edward Cedrone, Marina A. Dobrovolskaia, Mihály Józsi and János Szebeni.
Publicado en: Front. Immunol, Edición 12, 2021, ISSN 1664-3224
Editor: Front. Immunol
DOI: 10.3389/fimmu.2021.642860

To “PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives

Autores: Shi D, Beasock D, Fessler A, Szebeni J, Ljubimova JY, Afonin KA, Dobrovolskaia MA
Publicado en: Advanced Drug Delivery Reviews, Edición 180, 2022, Página(s) 22, ISSN 0169-409X
Editor: Elsevier BV
DOI: 10.1016/j.addr.2021.114079

The Hypertensive Effect of Amphotericin B-Containing Liposomes (Abelcet) in Mice: Dissecting the Roles of C3a and C5a Anaphylatoxins, Macrophages and Thromboxane

Autores: Orfi E, Hricisak L, Dezsi L, Hamar P, Benyo Z, Szebeni J, Szenasi G
Publicado en: Biomedicines, Edición 10(7), 2022, Página(s) 1764, ISSN 2227-9059
Editor: MDPI AG
DOI: 10.3390/biomedicines10071764

Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG

Autores: Kozma TG, Meszaros T, Berenyi P, Facsko R, Patko Zs, Oláh Cs, Nagy J, Fulop T, Glatter K, Radovits T, Merkely B, Szebeni J.
Publicado en: Vaccine, Edición 41, 2023, Página(s) 4561-4570, ISSN 0264-410X
Editor: Elsevier BV
DOI: 10.1016/j.vaccine.2023.06.009

Nanocarriers as a Tool for the Treatment of Colorectal Cancer

Autores: Ana Luiza C. de S. L. Oliveira, Timo Schomann, Lioe-Fee de Geus-Oei, Ellen Kapiteijn, Luis J. Cruz, Raimundo Fernandes de Araújo Junior
Publicado en: Pharmaceutics, Edición 13/8, 2021, Página(s) 1321, ISSN 1999-4923
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics13081321

Insights into the Structure of Comirnaty Covid-19 Vaccine: A Theory on Soft, Partially Bilayer-Covered Nanoparticles with Hydrogen Bond-Stabilized mRNA–Lipid Complexes

Autores: Szebeni, J;Kiss, B;Bozo, T;Turjeman, K;Levi-Kalisman, Y;Barenholz, Y;Kellermayer, M
Publicado en: ACS NANO, Edición 17, 2023, Página(s) 13147-13157, ISSN 1936-0851
Editor: American Chemical Society
DOI: 10.1021/acsnano.2c11904